Financing co-led by Novo Holdings and an international investor consortium consisting of Sanofi Ventures, Sofinnova, LSP, Droia Ventures, V-Bio Ventures and Polaris Partners.
The biotech company Muna Therapeutics obtains EUR 60 million equivalent to DKK 450 million in a series A round from Novo Holdings A/S and an international investor consortium consisting of Sanofi’s venture fund, Sanofi Ventures, and Sofinnova Partners (France), LSP(the Netherlands), Droia Ventures (Belgium), V-Bio Ventures (Belgium) and Polaris Partners (USA).
The investment is going to be used for the development of the company’s drug candidates against Alzheimer's disease, Parkinson's disease and dementia.
Horten has advised the investor consortium with a team headed by Hans Christian Pape, Marie Funch Lind and Malene Høj Hansen.